Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunomedics, Inc.
Monoclonal antibody developer reports positive ruling from Nasdaq panel
October 9th, 2005
Immunomedics, Inc., (IMMU) has received a letter from The Nasdaq Stock Market notifying the company that the Nasdaq Listing and Qualification Panel has ruled in favor of the company. As a result, the company will remain listed on the Nasdaq National Market. "We are pleased with the positive ruling from the Nasdaq panel. Our stock has been listed on The Nasdaq Stock Market for over 20 years and we look forward to continue working with Nasdaq," commented Cynthia L. Sullivan, president and CEO of the company. The letter from Nasdaq is related to the Nasdaq Listing Qualification Staff's decision on June 10, 2005, to delist the...
Source: Managed Care Law Weekly (2005-10-09)
|
